Härmark L, van Grootheest A C
Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 's-Hertogenbosch, The Netherlands.
Eur J Clin Pharmacol. 2008 Aug;64(8):743-52. doi: 10.1007/s00228-008-0475-9. Epub 2008 Jun 4.
Pharmacovigilance, defined by the World Health Organisation as 'the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem' plays a key role in ensuring that patients receive safe drugs. Our knowledge of a drug's adverse reactions can be increased by various means, including spontaneous reporting, intensive monitoring and database studies. New processes, both at a regulatory and a scientific level, are being developed with the aim of strengthening pharmacovigilance. On a regulatory level, these include conditional approval and risk management plans; on a scientific level, transparency and increased patient involvement are two important elements.
To review and discuss various aspects of pharmacovigilance, including new methodological developments.
世界卫生组织将药物警戒定义为“与药物不良反应或任何其他药物相关问题的发现、评估、理解及预防有关的科学与活动”,其在确保患者使用安全药物方面发挥着关键作用。我们可以通过多种方式增加对药物不良反应的了解,包括自发报告、强化监测和数据库研究。为加强药物警戒,监管和科学层面都在开发新流程。在监管层面,这些措施包括有条件批准和风险管理计划;在科学层面,透明度和患者更多参与是两个重要因素。
回顾并讨论药物警戒的各个方面,包括新的方法学进展。